Receptor occupancy in myocardium, adrenal cortex, and brain by TH- 142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect

Pharmaceutical Research

Volumn 15, Issue 6, 1998, Pages 911-917

  Nozawa, Yoshihisa ^a   Miyake, Hidekazu ^a   Yamada, Shizuo ^b   Kimura, Ryohei ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Angiotensin II receptor antagonist; Ex vivo receptor occupancy; Pharmacodynamics; Pharmacokinetics; Rat tissues; TH 142177

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN RECEPTOR; LOSARTAN; N,N BUTYL N [2' (1 H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL (N CARBOXYMETHYL BENZYLAMINO)ACETAMIDE; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; HEART MUSCLE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; RENOVASCULAR HYPERTENSION;

ADRENAL CORTEX; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; GLYCINE; IMIDAZOLES; LOSARTAN; MALE; MYOCARDIUM; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0031780254     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011932800729     Document Type: Article

References (19)

1. M. B. Vallotton. The renin angiotensin system. Trends Pharmacol. Sci. 8:69-74 (1987).
2. H. G. Williams. Converting enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319:1517-1525 (1988).
3. H. R. Brunner, Y. Christen, A. Munafo, R. J. Lee, B. Waeber, and J. Nussberger. Clinical experience with angiotensin II receptor antagonists. Am. J. Hypertens. 12: 243S-246S (1992).
4. 1 receptor antagonist. Fundam. Clin. Pharmacol. 11:395-401 (1997).
5. H. T. Beauchamp, R. S. L. Chang, P. K. S. Siegl, and R. E. Gibson. In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: Relationship to in vitro affinities and in vivo pharmacologic potency. J. Pharmacol. Exp. Ther. 272:612-618 (1995).
6. S. Uchida, S. Yamada, T. Ohkura, M. Heshikiri, A. Yoshimi, H. Shirahase, and R. Kimura. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats. Br. J. Pharmacol. 114:217-223 (1995).
7. S. Yamada, Y. Matsuoka, Y. Kato, R. Kimura, and O. Inagaki. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 262:589-594 (1992).
8. S. Yamada, N. Sugimoto, S. Uchida, Y. Deguchi, and R. Kimura. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J. Cardiovasc. Pharmacol. 23:466-472 (1994).
9. Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano. Kinetics of receptor occupation and anticonvulsive effects of diazepam in rats. Drug Metab. Dispos. 13:102-106 (1985).
10. H. Ishizuka, Y. Sawada, K. Ito, Y. Sugiyama, H. Suzuki, T. Iga, and M. Hanano, Nonlinear relationship between benzodiazepine receptor occupancy and glucose metabolic response in the conscious mouse brain in vivo. J. Pharmacol. Exp. Ther. 251:362-367 (1989).
11. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).
12. L. A. Sechi, C. A. Griffin, E. F. Grady, J. E. Kalinyak, and M. Schambelan. Characterization of angiotensin II receptor subtypes in rat heart. Circ. Res. 71:1482-1489 (1992).
13. Y. Nozawa, A. Haruno, N. Oda, Y. Yamasaki, N. Matsuura, S. Yamada, K. Inabe, R. Kimura, H. Suzuki, and T. Hoshino, Angiotensin II receptor subtypes in bovine and human ventricular myocardium. J. Pharmacol. Exp. Ther. 270:566-571 (1994).
14. 3H]WB4101: effect of 6-hydroxydopamine treatment. J. Pharmacol. Exp. Ther. 215:176-185 (1980).
15. J. W. Regan, W. R. Roeske, J. B. Malick, S. H. Yamamura, and H. I. Yamamura. γ-Aminobutyric acid enhancement of CL 218,872 affinity and evidence of benzodiazepine receptor heterogeneity. Mol. Pharmacol. 20:477-483 (1981).
16. P. B. M. W. M. Timmermans, P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. R. Wexler, J. A. M. Saye, and R. D. Smith. Angiotensin II receptors and angiotensm II receptor antagonists. Pharmacol. Rev. 45:205-251 (1993).
17. F. H. Marshall, S. A. Clark, A. D. Michel, and J. C. Barnes. Binding of angiotensin antagonists to rat liver and brain membranes measured ex vivo. Br. J. Pharmacol. 109:760-764 (1993).
18. 1 receptor antagonist, losartan (DuP 753) on cognitive performance in the radial maze and in a delayed non-matching to position task in the rat. Br. J. Pharmacol. 105:88P(1992).
19. P. C. Wong, J. R. Price, A. T. Chiu, J. V. Duncia, D. J. Carini. R. R. Wexler, A. L. Johnson, and P. B. W. M. Timmermans. Nonpeptide angiotensin II receptor antagonists. IX. Pharmacology of EXP3174: an active metabolite of DuP 753. an orally active antihypertensive agent. J. Pharmacol. Exp. Ther. 255:211-217 (1990).